Joseph Liao, None;
Carolina Gracitelli, None;
Linda Zangwill, Carl Zeiss Meditec, Inc. (F), Carl Zeiss Meditec, Inc. (P), Heidelberg Engineering, GmbH (F), Nidek (F), Quark Pharmaceuticals, Inc. (F), Topcon, Inc. (F);
Christopher Girkin, Carl Zeiss Meditec, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F), SOLX (F);
Jeffrey Liebmann, Alcon, Inc. (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc. (F), Diopysis, Inc. (C), Diopysis, Inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Pharmaceuticals, Inc. (C), Optovue, Inc. (F), Quark Pharmaceuticals, Inc. (F), Reichert, Inc. (F), Sensimed, Inc. (F), Topcon, Inc. (F), Valeant Pharmaceuticals (C);
Robert Weinreb, Alcon, Inc. (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Carl Zeiss Meditec, Inc. (C), Carl Zeiss Meditec, Inc. (R), Genentech (R), Heidelberg Engineering, Inc. (R), Nidek (R), Novartis (R), Optovue, Inc. (R), Sensimed, Inc. (C), Topcon, Inc. (C), Topcon, Inc. (R);
Felipe Medeiros, Alcon, Inc. (F), Alcon, Inc. (R), Allergan, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (R), Bausch & Lomb, Inc. (F), Carl Zeiss Meditec, Inc. (C), Carl Zeiss Meditec, Inc. (F), Carl Zeiss Meditec, Inc. (R), Heidelberg Engineering, Inc. (F), Merck, Inc. (F), National Eye Institute (F), Novartis (C), Reichert, Inc. (F), Reichert, Inc. (R), Sensimed, Inc. (F), Topcon, Inc. (F)